Yahoo Finance • 11 days ago
* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20241081-inmed-pharmaceuticals-reports-full-year-fiscal-2025-financial-results-and-provides-business] (NASDAQ:INM [https://seekingalpha.com/symbol/INM]): FY GAAP EPS of -... Full story
Yahoo Finance • 16 days ago
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now a... Full story
Yahoo Finance • 3 months ago
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story
Yahoo Finance • 3 months ago
* InMed Pharmaceuticals (NASDAQ:INM [https://seekingalpha.com/symbol/INM]) has entered into definitive agreements for the issuance and sale of 1.95M of its common shares and short-term preferred investment options to purchase up to an ag... Full story
Yahoo Finance • 3 months ago
VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ:INM), a micro-cap pharmaceutical company with a market capitalization of approximately $3 million, announced Tuesday that its drug candidate INM-901 significantly reduced inflammation markers... Full story
Yahoo Finance • 4 months ago
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo... Full story
Yahoo Finance • 3 years ago
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companie... Full story
Yahoo Finance • 3 years ago
Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzh... Full story
Yahoo Finance • 3 years ago
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 3 years ago
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’sIdentified two lead cannabinoid analog compounds for in vivo studiesNSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar f... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabino... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, to... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleas... Full story
Yahoo Finance • 3 years ago
Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story
Yahoo Finance • 3 years ago
VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today an... Full story